Tevogen Bio Leads in Developing Cell Therapies to Eradicate HPV in Women with Precancerous Cervical Lesions

Approximately one-third of women remain HPV positive after undergoing treatment for precancerous cervical lesions. Each year, tens of thousands of women in the United States are diagnosed with high-grade cervical precancerous lesions, which carry the risk of recurrence and further treatment, potentially leading to cervical cancer. High-grade cervical lesions and nearly all cervical cancer cases are associated with HPV, a virus that fosters cancer development. The persistence of HPV post-treatment is the primary risk factor for the recurrence of these lesions. HPV, the world’s most common sexually transmitted infection, poses a significant public health issue as it can lead to cancers in the cervix and other body areas like the mouth and throat.

Tevogen Bio, a company based in Warren, New Jersey, is working on TVGN 920, a T cell therapy aimed at treating HPV in women with precancerous cervical lesions. This pioneering therapy is being developed using Tevogen’s proprietary ExacTcell™ technology. This technology utilizes genetically unmodified, allogeneic cytotoxic CD8+ T cells targeting specific areas of the HPV genome. TVGN 920 will undergo safety and feasibility studies to assess its potential effectiveness in treating HPV and preventing the recurrence of high-grade cervical lesions.

The company’s goal with TVGN 920 is to eliminate HPV to prevent the reappearance of cervical lesions that could develop into cervical cancer and to stop the transmission of the virus. Dr. Dolores Grosso, the Clinical Development Lead at Tevogen, emphasized that eradicating HPV in women could prevent recurrent cervical pathology and potentially cervical cancer, while also disrupting the cycle of HPV transmission, which is a significant public health concern. Dr. Neal Flomenberg, Tevogen’s Chief Scientific Officer, highlighted that many cancers are triggered by viral infections and expressed hope that their efforts would lead to new treatments for other virus-associated cancers.

Tevogen Bio is dedicated to making personalized immunotherapies accessible to large patient populations affected by common cancers and viral infections. The company’s research pipeline includes treatments for HPV and other serious viral infections and cancers using their precision T cell platform. Dr. Ryan Saadi, the company’s founder and CEO, and a 2023 Nobel Peace Prize nominee, stated that Tevogen aims to harness the vast potential of personalized immunotherapies for widespread patient benefit.

Tevogen Bio operates as a clinical-stage specialty immunotherapy company, leveraging CD8+ cytotoxic T lymphocytes to create off-the-shelf, genetically unmodified T cell therapeutics for treating infectious diseases and cancers. The company’s leadership believes that achieving sustainability and commercial success in today’s healthcare landscape requires ensuring patient accessibility through advanced scientific methods and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and the company owns all of its key intellectual property assets, which include three granted patents and several pending ones, two of which involve artificial intelligence.

Guided by a team of seasoned industry leaders and scientists with extensive experience in drug development and global product launches, Tevogen believes that accessible personalized therapeutics represent the future of medicine. The company also believes that innovative business models are necessary to sustain medical advancements and that they are committed to addressing the unmet needs of large patient populations through their therapeutic developments.